Black Diamond Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Black Diamond Therapeutics will hold its 2024 Annual Meeting of Stockholders online on June 6, 2024, to elect directors, ratify auditors, and approve amendments to its charter.</b>

AI Summary

Black Diamond Therapeutics, Inc. (BDTX) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. The 2024 Annual Meeting of Stockholders for Black Diamond Therapeutics, Inc. will be held online on June 6, 2024. The meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/BDTX2024. Stockholders will vote on the election of two Class I director nominees. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified. An amendment to the Fourth Amended and Restated Certificate of Incorporation to limit officer liability will be proposed for approval.

Why It Matters

For investors and stakeholders tracking Black Diamond Therapeutics, Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and proposals for the upcoming annual meeting, which is crucial for shareholder governance and decision-making. The virtual-only format aims to enhance stockholder access and participation, allowing for electronic voting and question submission from any location.

Risk Assessment

Risk Level: low — Black Diamond Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.

Analyst Insight

Stockholders should review the proposals, particularly the director elections and charter amendment, and participate in the virtual meeting to exercise their voting rights.

Key Numbers

• 2 — Director Nominees (Number of Class I director nominees to be elected.)
• 2027 — Director Term (Year until which elected directors will serve.)
• 2024 — Fiscal Year End (Fiscal year for which PricewaterhouseCoopers LLP is proposed as auditor.)

Key Players & Entities

• Black Diamond Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
• June 6, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
• PricewaterhouseCoopers LLP (company) — Proposed independent registered public accounting firm.
• Delaware (jurisdiction) — State of incorporation and law governing the certificate of incorporation amendment.

FAQ

Risk Factors

• Proxy Statement Filing [low — regulatory]: The filing is a routine DEF 14A proxy statement, indicating compliance with SEC regulations for annual meetings.

Industry Context

Black Diamond Therapeutics is a biotechnology company focused on developing therapies. Annual meetings are standard corporate governance events for public companies.

Regulatory Implications

The filing adheres to SEC regulations for proxy solicitations (Schedule 14A) to ensure transparent communication with shareholders regarding meeting proposals.

What Investors Should Do

1. Review the biographies and qualifications of the two Class I director nominees.
2. Understand the implications of the proposed amendment to the Certificate of Incorporation regarding officer liability.
3. Prepare to vote electronically during the virtual meeting on June 6, 2024.

Key Dates

• 2024-06-06: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and decision-making on corporate matters.
• 2024-04-24: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Glossary

DEF 14A

Definitive Proxy Statement filed under Section 14(a) of the Securities Exchange Act of 1934. (This is the primary document outlining the agenda and proposals for the annual shareholder meeting.)

Class I Director Nominees

Nominees for specific positions on the company's board of directors. (Shareholders vote on these nominees to fill board seats and influence company strategy.)

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, distinct from previous filings which would have covered different reporting periods or events.

Key Financial Figures

• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
• $0.0001 — 4 shares of our common stock, par value $0.0001 per share, outstanding on April 9, 2024

Filing Documents

• tm242799-2_def14a.htm (DEF 14A) — 749KB
• lg_blackdiamond-4c.jpg (GRAPHIC) — 13KB
• px_24blackpxy01pg01-4c.jpg (GRAPHIC) — 222KB
• px_24blackpxy01pg02-bw.jpg (GRAPHIC) — 203KB
• 0001104659-24-051211.txt (&nbsp;) — 1300KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 30 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 39 REPORT OF THE AUDIT COMMITTEE 45 HOUSEHOLDING 46 STOCKHOLDER PROPOSALS 46 WHERE YOU CAN FIND MORE INFORMATION 47 ANNUAL REPORT 47 OTHER MATTERS 47 APPENDIX A A-1 TABLE OF CONTENTS BLACK DIAMOND THERAPEUTICS, INC. One Main Street, 14 th Floor Cambridge, MA 02142 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 6, 2024 This proxy statement contains information about the 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Black Diamond Therapeutics, Inc., which will be held on June 6, 2024 at 9:00 a.m. Eastern Time. The Annual Meeting will be a virtual meeting, which will be conducted via live webcast. You may attend the meeting online, vote your shares electronically and submit questions by visiting www.virtualshareholdermeeting.com/BDTX2024. The board of directors of Black Diamond Therapeutics, Inc., or our board of directors, is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms "Black Diamond Therapeutics," "Black Diamond," the "Company," "we," "us," "our," and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiary. The mailing address of our principal executive offices is Black Diamond Therapeutics, Inc., One Main Street, 14 th Floor, Cambridge, MA 02142. Please see the "General Information" section of this proxy statement for more details regarding the logistics of the virtual Annual Meeting, including the ability of stockholders to submit questions during the Annual Meeting, and technical details and support related to accessing the virtual platform. You will not be able to attend the 2024 Annual Meeting in person. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in a

View Full Filing

View this DEF 14A filing on SEC EDGAR